Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy plus TCM-001 vs placebo in first-line unresectable pancreatic cancer
ChiCTR2400092573Phase 2Completed
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Nov 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing Chemotherapy + TCM-001 with Chemotherapy + placebo (2 arms). Primary endpoint: Overall survival. Started Nov 2024; status: completed.
02
Drugs
TCM-001
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2400092573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092573.